EXPRESSION OF THE C-MET PROTOONCOGENE IN HUMAN HEPATOCELLULAR-CARCINOMA

被引:2
|
作者
SUZUKI, K
HAYASHI, N
YAMADA, Y
YOSHIHARA, H
MIYAMOTO, Y
ITO, Y
ITO, T
KATAYAMA, K
SASAKI, Y
ITO, A
KISIDA, Y
KASHIWAGI, T
FUSAMOTO, H
KAMADA, T
机构
[1] OSAKA UNIV,SCH MED,DEPT MED 1,SUITA,OSAKA 565,JAPAN
[2] OSAKA ROSAI HOSP,SAKAI,OSAKA 591,JAPAN
[3] OSAKA KOSEINENKIN HOSP,OSAKA 553,JAPAN
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The c-met protooncogene is a growth factor receptor with tyrosine kinase activity. Recently the hepatocyte growth factor was identified as the ligand for this receptor. Because the hepatocyte growth factor is a most potent mitogen in hepatocytes, possible involvement of c-met expression in hepatocarcinogenesis is suspected. In this study, we examined c-met expression in 23 hepatocellular carcinoma cases by means of Northern-blot analysis and an immunohistochemical study. Northern-blot analysis revealed c-met mRNA expression in the tumors of 6 of 19 patients (31.6%); in the immunohistochemical study, c-net protein was detected in 16 of 23 patients (69.6%). With both methods, c-met was found to be overexpressed in hepatocellular carcinoma compared with the surrounding normal liver. Comprehensive analysis showed that c-met protein expression was correlated with poor-to moderate differentiation of cancer cells (p < 0.05). Tumor proliferative activity of hepatocellular carcinoma was evaluated by means of Ki-67 labeling index. All cases with increased tumor proliferative activity showed c-met protein expression, although the elevation of proliferative activity in the c-met-positive group was not statistically significant. These data suggest that the overexpression of c-met plays an important role in the development of hepatocellular carcinoma.
引用
收藏
页码:1231 / 1236
页数:6
相关论文
共 50 条
  • [21] Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma
    Shunsuke Kondo
    Hidenori Ojima
    Hitoshi Tsuda
    Jun Hashimoto
    Chigusa Morizane
    Masafumi Ikeda
    Hideki Ueno
    Kenji Tamura
    Kazuaki Shimada
    Yae Kanai
    Takuji Okusaka
    International Journal of Clinical Oncology, 2013, 18 : 207 - 213
  • [22] Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
    Goyal, Lipika
    Muzumdar, Mandar D.
    Zhu, Andrew X.
    CLINICAL CANCER RESEARCH, 2013, 19 (09) : 2310 - 2318
  • [23] The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
    Wang, Haiyu
    Rao, Benchen
    Lou, Jiamin
    Li, Jianhao
    Liu, Zhenguo
    Li, Ang
    Cui, Guangying
    Ren, Zhigang
    Yu, Zujiang
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [24] Caveolin and c-met interaction in hepatocellular carcinoma cells
    Cokakli, M.
    Erdal, E.
    Sagol, O.
    Karademir, S.
    Atabey, N.
    FEBS JOURNAL, 2006, 273 : 104 - 104
  • [25] c-Met: A potential therapeutic target for hepatocellular carcinoma
    Gao, Jianjun
    Inagaki, Yoshinori
    Xue, Xia
    Qu, Xianjun
    Tang, Wei
    DRUG DISCOVERIES AND THERAPEUTICS, 2011, 5 (01): : 2 - 11
  • [26] Absence of tpr-met and expression of c-met in human gastric mucosa and carcinoma
    Heideman, DAM
    Snijders, PJF
    Bloemena, E
    Meijer, CJLM
    Offerhaus, GJA
    Meuwissen, SGM
    Gerritsen, WR
    Craanen, ME
    JOURNAL OF PATHOLOGY, 2001, 194 (04): : 428 - 435
  • [27] HLA EXPRESSION IN HUMAN HEPATOCELLULAR-CARCINOMA
    PATERSON, AC
    SCIOT, R
    KEW, MC
    CALLEA, F
    DUSHEIKO, GM
    DESMET, VJ
    BRITISH JOURNAL OF CANCER, 1988, 57 (04) : 369 - 373
  • [28] c-MET and HGF mRNA Expression in Hepatocellular Carcinoma: Correlation with Clinicopathological Features and Survival
    Ang, Celina Su-Ping
    Sun, Mark Yipin
    Fidel Huitzil-Melendez, David
    Chou, Joanne Fu-Lou
    Capanu, Marinela
    Jarnagin, William
    Fong, Yuman
    Dematte, Ronald Paul
    D'Angelica, Michael
    Allen, Peter
    Chen, Chin-Tung
    O'Reilly, Eileen Mary
    Weiser, Martin Ross
    Abou-Alfa, Ghassan Khaled
    ANTICANCER RESEARCH, 2013, 33 (08) : 3241 - 3245
  • [29] Tumor c-Met expression and prognosis of advanced hepatocellular carcinoma patients treated with sorafenib
    Shao, Yu Yun
    Hsiao, Chi-Huang
    Lee, Ray
    Puig, Oscar
    Chan, Soa-Yu
    Li, Yong-Shi
    Hsu, Chih-Hung
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [30] Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma
    Chun, Hyung-Wook
    Hong, Ran
    ONCOLOGY LETTERS, 2019, 17 (06) : 5487 - 5498